Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

bouchardatine

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Non‐alcoholic hepatic fatty liver disease (NAFLD) is a manifestation of the metabolic syndrome in the liver and non‐alcoholic… Expand
2019
2019
Cancer metabolism is an attractive target of the therapeutic strategy for cancer. The present study identified bouchardatine (Bou… Expand
2019
2019
BACKGROUND AND PURPOSE Non-alcoholic hepatic fatty liver disease (NAFLD) is a manifestation of metabolic syndrome (MetS) in liver… Expand
2018
2018
Inhibition of the differentiation of adipocytes and reduced lipid synthesis are efficacious approaches for treating obesity… Expand
2017
2017
Promoting energy metabolism is known to provide therapeutic effects for obesity and associated metabolic disorders. The present… Expand
2015
2015
Our recent study has shown that the natural product bouchardatine (1) can reduce the triglyceride (TG) content in 3T3-L1… Expand
2015
2015
Bouchardatine (1), a naturally occurring β-indoloquinazoline alkaloid, was synthesized. For the first time, the lipid-lowering… Expand
2011
2011
  • M. Bubenyák
  • Acta pharmaceutica Hungarica
  • 2011
  • Corpus ID: 27009155
Quinazolinocarboline rutaecarpine and evodiamine (Evodia rutaecarpa) are main alkaloid components of traditional Chinese folk… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2003
Highly Cited
2003
Five alkaloids, four beta-indoloquinazoline and one furoquinoline, and four terpenoids, three limonoids and one modified… Expand